Review

Mucosal Tolerance to Prevent Type 1 Diabetes: Can the Outcome Be Improved in Humans?

Arno Hanninen¹, Leonard C. Harrison²

Keywords: type 1 diabetes, immune intervention, mucosal tolerance, DPT-1 trial, CD40, T cells

Abstract

The results of trials in which autoantigens have been fed to individuals affected by autoimmune diseases - multiple sclerosis, rheumatoid arthritis and type 1 diabetes - have been disappointing in terms of clinical improvement. This is in striking contrast to the results in experimental rodent models of these diseases. The outcome of the recent DPT-1 trial testing oral insulin in individuals at risk of type 1 diabetes was also disappointing, in contrast to the effects of oral insulin in the non-obese diabetic (NOD) mouse model of type 1 diabetes. However, it is premature to conclude that mucosal tolerance works only in in-bred rodents and not in humans with autoimmune disease. Except for oral insulin in DPT-1, the human trials were performed in individuals with end-stage disease when this form of immune regulation might not be expected to be effective. Importantly, in no trial was an immune response to the autoantigen documented, to demonstrate that the dose was at least bioavailable. Furthermore, mucosal autoantigen administration is a 'double-edged sword' and in rodents can lead not only to regulatory and protective immunity but also to pathogenic, tissue-destructive immunity and exacerbation of autoimmune disease. When suppression of autoimmune disease is observed it may be because autoantigen was administered under conditions which minimize induction of pathogenic immunity. Thus, clinical protocols for mucosal autoantigen administration may need to be modified to favor induction of regulatory immunity. In this short review, we discuss recent studies in autoimmune diabetes-prone NOD mice indicating that with novel modifications mucosal autoantigen administration could be harnessed to prevent type 1 diabetes in humans.

Fulltext: HTML , PDF (1.2 MB)

This article has been cited by other articles:

	Glutamic acid decarboxylase epitope protects against autoimmune diabetes through activation of Th2 immune response and induction of possible regulatory mechanism Gong Z, Pan L, Le Y, Liu Q, Zhou M, Xing W, Zhuo R, Wang S, Guo J Vaccine 2010. 28(24):4052-4058
	Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis Czaja AJ Dig Dis Sci 2010. 55(10):2712-2726
	Animal models of autoimmune hepatitis Czaja AJ Expert Rev Gastroenterol Hepatol 2010. 4(4):429-443
	Oral tolerance: Can we make it work? Ilan Y Hum Immunol 2009. 70(10):768-776
	Long term immunologic consequences of experimental stroke and mucosal tolerance Gee JM, Zierath D, Hadwin J, Savos A, Kalil A, Thullbery M, Becker KJ Exp Transl Stroke Med 2009. 1:3
	The Role of Regulatory T Cell Defects in Type I Diabetes and the Potential of these Cells for Therapy Thomas D, Zaccone P, Cooke A Rev Diabet Stud 2005. 2(1):9-18
	Tolerance Induction and Endogenous Regeneration of Pancreatic Beta-Cells in Established Autoimmune Diabetes Sia C, Homo-Delarche F Rev Diabet Stud 2004. 1(4):198-206